Skip to main content
SpringerLink
Log in

Empfehlungen der Deutschen Gesellschaft für Palliativmedizin (DGP)

Klug entscheiden am Lebensende

  • Palliativmedizin
  • Fortbildung
  • Published:
Im Focus Onkologie Aims and scope

Die Gratwanderung zwischen Über- und Unterversorgung in der letzten Lebensphase birgt ein Vielzahl medizinischer und ethischer Herausforderungen. Die Deutsche Gesellschaft für Palliativmedizin hat Empfehlungen ausgesprochen, um schwerkranke und sterbende Patienten bestmöglich zu behandeln.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bundesärztekammer. Grundsätze der Bundesärztekammer zur ärztlichen Sterbebegleitung Präambel. Dtsch Arztebl. 2011; 108(7):A-346/B-278/C-278.

  2. Alt-Epping B. KLUG ENTSCHEIDEN: ... in der Palliativmedizin. Dtsch Arztebl. 2016;113(42):A-1870/B-1575/C-1563.

  3. Stellungnahme der Bundesärztekammer „Medizinische Indikationsstellung und Ökonomisierung“: www.bundesaerztekammer.de/fileadmin/user_upload/downloads/pdf-Ordner/Stellungnahmen/Stn_Medizinische_Indikationsstellung_und_OEkonomisierung.pdf

  4. Bundesgerichtshof. AZ XII ZB 2/03. Neue Jurist Wochenschr. 2003;56:1588-94.

  5. Raspe H. Ethische Aspekte der Indikation. In: Toellner R, Wiesing U, Hrsg. Wissen — Handeln — Ethik. Strukturen ärztlichen Handelns und ihre ethische Relevanz. Stuttgart Jena New York: Fischer; 1995. S. 21-36.

  6. Sahm S. Autonomie, ärztliche Indikation und Entscheidungsfindung. In: Charbonnier R, Dörner K, Simon S, Hrsg. Medizinische Indikation und Patientenwille. Stuttgart New York: Schattauer; 2008. S.121-31.

  7. Winkler E. Ist ein Therapieverzicht gegen den Willen des Patienten ethisch begründbar? Ethik Med. 2010;22(2):89–102.

    Article  Google Scholar 

  8. Alt-Epping B, Nauck F. Der Wunsch des Patienten — ein eigenständiger normativer Faktor in der klinischen Therapieentscheidung? Ethik Med. 2012;24(1):19–28.

    Article  Google Scholar 

  9. Raijmakers NJH et al. Artificial nutrition and hydration in the last week of life in cancer patients. A systematic literature review of practices and effects. Ann Oncol. 2011; 22(7):1478–86.

    Article  CAS  PubMed  Google Scholar 

  10. Bruera E et al. Parenteral hydration in patients with advanced cancer: a multicenter, doubleblind, placebo-controlled randomized trial. J Clin Oncol. 2013;31(1):111–8.

    Article  PubMed  Google Scholar 

  11. Nakajima N et al. A clinical study on the influence of hydration volume on the signs of terminally ill cancer patients with abdominal malignancies. J Palliat Med. 2013; 16(2):185–9.

    Article  PubMed  Google Scholar 

  12. Breuer B et al. Medical oncologists’ attitudes and practice in cancer pain management: a national survey. J Clin Oncol. 2011; 29(36):4769–75.

    Article  PubMed  Google Scholar 

  13. Deandrea S et al. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol. 2008;19(12):1985–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Sabatowski R et al. Tumorschmerztherapie in Deutschland: Ergebnisse und Analysen einer Befragung von Ärzten. Schmerz. 2001;15(4):241–7.

    Article  CAS  PubMed  Google Scholar 

  15. Sapir R et al. Cancer pain: knowledge and attitudes of physicians in Israel. J Pain Symptom Manage. 1999;17(4):266–76.

    Article  CAS  PubMed  Google Scholar 

  16. Von Roenn JH et al. Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med. 1993;119(2):121–6.

    Article  CAS  PubMed  Google Scholar 

  17. Alt-Epping B et al. Schmerztherapie in der Onkologie — eine bundesweite Umfrage unter der Schirmherrschaft der Deutschen Gesellschaft für Hämatologie/Onkologie. Schmerz. 2014;28(2):157–65.

    Article  CAS  PubMed  Google Scholar 

  18. Abernethy AP et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. Br Med J. 2003;327(7414):523–6.

    Article  CAS  Google Scholar 

  19. Jennings AL et al. Opioids for the palliation of breathlessness in terminal illness. Cochrane Database Syst Rev. 2001; 4:CD002066.

    Google Scholar 

  20. Johnson MJ et al. Morphine for the relief of breathlessness in patients with chronic heart failure — a pilot study. Eur J Heart Fail. 2002;4(6):753–6.

    Article  CAS  PubMed  Google Scholar 

  21. Mazzocato C et al. The effects of morphine on dyspnea and ventilator function in elderly patients with advanced cancer: a randomized double-blind controlled trial. Ann Oncol. 1999;10(12):1511–4.

    Article  CAS  PubMed  Google Scholar 

  22. S3-Leitlinie Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung, Langversion 1.0, 2015, AWMF-Registernummer: 128/001OL. http://www.awmf.org/uploads/tx_szleitlinien/128-001OLl_S3_Palliativmedizin_2015-07.pdf.

  23. Bakitas MA et al. Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol. 2015; 33(13):1438–45.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Johnsen AT et al. Detailed statistical analysis plan for the Danish Palliative Care Trial (DanPaCT). Trials. 2014;15:376.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Zimmermann C. Early palliative care for patients with advanced cancer: a clusterrandomised controlled trial. Lancet. 2014; 83(9930):1721–30.

    Article  Google Scholar 

  26. Temel J et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733–42.

    Article  CAS  PubMed  Google Scholar 

  27. Gómez-Batiste X et al. Prevalence and characteristics of patients with advanced chronic conditions in need of palliative care in the general population: a cross-sectional study. Palliat Med. 2014;28(4):302–11.

    Article  PubMed  Google Scholar 

  28. Ostgathe C et al. Hospice and Palliative Care Evaluation (HOPE) Working Group in Germany. Non-cancer patients in specialised palliative care in Germany: What are the problems? Palliat Med. 2011;2582):148–52.

    Article  Google Scholar 

  29. Alt-Epping B et al. Palliativmedizinische Konzepte bei nicht-onkologischen Grunderkrankungen. Dtsch Med Wochenschr. 2008;133(34/35):1745–9.

    Article  CAS  PubMed  Google Scholar 

  30. Bee PE et al. A systematic review of informal caregivers’ needs in providing home-based end-of-life care to people with cancer. J Clin Nurs. 2009:18(10):1379–93.

    Article  PubMed  Google Scholar 

  31. Docherty A et al. Knowledge and information needs of informal caregivers in palliative care: a qualitative systematic review. Palliat Med. 2008;22(2):153–71.

    Article  PubMed  Google Scholar 

  32. Moss AH et al. Prognostic significance of the „surprise“ question in cancer patients. J Palliat Med. 2010;13(7):837–40.

    Article  PubMed  Google Scholar 

  33. Murray SA et al. Palliative care in chronic illness. BMJ. 2005;330(7492):611–2.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Candy B et al. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2011;19;(1):CD003448.

    Google Scholar 

  35. http://choosingwisely.org/societies

  36. http://aahpm.org/outreach/choosing-wisely

  37. http://www.choosingwiselycanada.org

  38. Schulz C. Interventionen bei Kernsymptomen — Angst, in Psychologie und Palliative Care. Stuttgart: Kohlhammer; 2012. S. 191-7.

  39. Schnipper LE et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012;30(14):1715–24.

    Article  PubMed  Google Scholar 

  40. Dodson JA et al. Patient preferences for deactivation of implantable cardioverterdefibrillators. JAMA Intern Med. 2013;173(5): 377–9.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Carlsson J et al. (2012) The deactivation of implantable cardioverter-defibrillators: medical, ethical, practical, and legal considerations. Dtsch Arztebl Int. 2012;109(33–34):535–41.

    PubMed  PubMed Central  Google Scholar 

  42. Fromme EK et al. Adverse experiences with implantable defibrillators in Oregon hospices. Am J Hosp Palliat Care. 2011;28(5):304–9.

    Article  PubMed  Google Scholar 

  43. Lampert R et al. HRS Expert Consensus Statement on the Management of Cardiovascular Implantable Electronic Devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm. 2010;7(7):1008–26.

    Article  PubMed  Google Scholar 

  44. Padeletti L et al. EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy. Europace. 2010; 12(10):1480–9.

    Article  PubMed  Google Scholar 

  45. Whellan DJ et al. Quality of Care Committee, Heart Failure Society of America. End-of-life care in patients with heart failure. J Card Fail. 2014;20(2):121–34.

    Article  PubMed  Google Scholar 

  46. McMurray JJ et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2012;33(14):1787–847.

    Article  PubMed  Google Scholar 

  47. Neitzke G. Unterscheidung zwischen medizinischer und ärztlicher Indikation. In: Charbonnier R, Dörner K, Simon S, Hrsg. Medizinische Indikation und Patientenwille. Stuttgart New York: Schattauer; 2008. S 53-66.

Download references

Author information

Authors and Affiliations

  1. Klinik für Palliativmedizin, Universitätsmedizin Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland

    Bernd Alt-Epping

Authors
  1. Bernd Alt-Epping
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernd Alt-Epping.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alt-Epping, B. Klug entscheiden am Lebensende. Im Focus Onkologie 21, 53–56 (2018). https://doi.org/10.1007/s15015-018-4050-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-018-4050-7

Search

Navigation